Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Treasury Shares (2018 - 2025)

IGC Pharma (IGC) has disclosed Treasury Shares for 8 consecutive years, with $6.5 million as the latest value for Q3 2025.

  • Quarterly Treasury Shares fell 11.77% to $6.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Sep 2025, down 11.77% year-over-year, with the annual reading at $5.8 million for FY2025, 22.22% down from the prior year.
  • Treasury Shares for Q3 2025 was $6.5 million at IGC Pharma, roughly flat from $6.5 million in the prior quarter.
  • The five-year high for Treasury Shares was $8.5 million in Q2 2023, with the low at $173000.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $5.7 million, with a median of $5.9 million recorded in 2022.
  • The sharpest move saw Treasury Shares crashed 90.65% in 2021, then soared 3322.54% in 2022.
  • Over 5 years, Treasury Shares stood at $5.8 million in 2021, then decreased by 0.63% to $5.8 million in 2022, then surged by 47.26% to $8.5 million in 2023, then fell by 14.77% to $7.3 million in 2024, then dropped by 10.79% to $6.5 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $6.5 million, $6.5 million, and $5.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.